AMAG CMO hits the exit just as biotech searches for new CEO to right a ship rocked by Makena controversy

Heading into 2020, AMAG Pharmaceuticals has sketched big plans to salvage its wobbly operations — battling a revenue squeeze and a critical FDA review of its preterm birth drug — under a new CEO. Today, it announced that the chief medical officer won’t be staying, either.